Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.82 |
| ▸ | RAB9A | P51151 | 12/20 | 0.74 |
| ▸ | NPC1 | O15118 | 10/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.70 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.70 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715768 | 0.90 | NAMPT (1.00) | NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5527547 | 0.85 | RAB9A (1.00) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL13717782 | 0.85 | RAB9A (0.62) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL30515325 | 0.84 | RAB9A (1.00) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL10226339 | 0.84 | RAB9A (1.00) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3698767 | 0.83 | RAB9A (0.79) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3699340 | 0.83 | NAMPT (0.84) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3700363 | 0.82 | RAB9A (0.78) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3708277 | 0.82 | RAB9A (1.00) | NAMPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL17559776 | 0.82 | RAB9A (0.78) | NAMPTRAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009073203-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122924-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885RAB9A 2177/4885NPC1 88/4885 |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPM8, TRPV2 | NAMPT 3073/4885RAB9A 1239/4885NPC1 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.